Format

Send to

Choose Destination
Postepy Dermatol Alergol. 2016 Dec;33(6):397-410. doi: 10.5114/pdia.2016.63942. Epub 2016 Dec 2.

The role and choice criteria of antihistamines in allergy management - expert opinion.

Author information

1
Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
2
Department of Otolaryngology with Division of Cranio-Maxillo-Facial Surgery, Military Institute of Medicine, Warsaw, Poland.
3
Department and Division of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
4
Department of Immunopathology, Division of Allergology, Immunopathology and Dermatology, Faculty of Biomedical Sciences and Postgraduate Training, Medical University of Lodz, Lodz, Poland.
5
Department of Clinical Pharmacology, Faculty of Medicine, Medical College Jagiellonian University, Krakow, Poland.
6
Department of Allergology and Internal Medicine, Faculty of Health Sciences, Medical University of Bialystok, Bialystok, Poland; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
7
Department of Lung Diseases and Rheumatology, 2 Faculty of Medicine, Medical University of Lublin, Lublin, Poland.

Abstract

Allergic diseases are the most common chronic conditions lasting throughout the patient's life. They not only cause significant deterioration in the quality of life of patients but also lead to significant absenteeism and reduced productivity, resulting in very high costs for society. Effective and safe treatment of allergic diseases is therefore one of the main challenges for public health and should be carried out by all the specialists in family medicine, internists and paediatricians in collaboration with allergists, otorhinolaryngologists and dermatologists. Antihistamines are most commonly used in the treatment of allergies. Several dozen drugs are available on the pharmaceutical market, and their generic forms are advertised widely as very effective drugs for the treatment of allergic diseases. What is the truth? What are the data from clinical trials and observational studies? Are all drugs equally effective and safe for the patient? According to a panel of experts representing various fields of medicine, inappropriate treatment of allergies can be very risky for patients, and seemingly equally acting medications may differ greatly. Therefore, a panel of experts gathered the latest data from the entire scientific literature and analysed the latest standards and recommendations prepared by scientific societies. This paper provides a summary of these studies and highlights the importance for the patient of the proper choice of drug to treat his allergies.

KEYWORDS:

allergic rhinitis; allergy; antihistamines; bilastin; urticaria

Conflict of interest statement

Piotr Kuna has during the last 3 years received honoraria for participating in advisory board meetings or giving lectures for the following companies: Adamed, Allergopharma, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Celon Pharma, Chiesi, FAES, Meda, MSD, Novartis, Pfizer, Polpharmex, Polpharma, Stallergen, Teva. Dariusz Jurkiewicz has during the last 3 years received honoraria for participating in advisory board meetings or giving lectures for the following companies: Adamed, Teva, Berlin-Chemie, Polpharma Magdalena Carnecka-Operacz has during the last 3 years received honoraria for participating in advisory board meetings or giving lectures for the following companies: Novartis, Berlin-Chemie, Leo, Meda, Pierre Fabre, Genactive, Allergopharma. Rafał Pawliczak has the conflict of interest that applies to lecture fees and advisory honoraria paid by Berlin-Chemie Menarini. Jarosław Woroń has during the last 3 years received honoraria for participating in advisory board meetings or giving lectures for the following companies: Berlin-Chemie/Menarini, MSD. Marcin Moniuszko has the conflict of interest that applies to received honoraria for participating during last 3 years in advisory board meetings or giving lectures for the following companies: Boehringer-Ingelheim, Berlin-Chemie/Menarini, Takeda, Symposion. Andrzej Emeryk reported lack of conflict of interest.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center